Eli Lilly-Backed Scribe Therapeutics Stuns Wall Street With a Rare Gene-Editing IPO -( $LLY $SCTX $SNY )

Eli Lilly-backed Scribe Therapeutics is having the kind of debut that makes Wall Street reach for a second coffee: the CRISPR company priced an upsized IPO, then saw its shares jump sharply in trading, a rare show of enthusiasm for an early-stage gene-editing name. The company now trades under the ticker SCTX, while Eli Lilly trades as LLY.

Why investors are paying attention

Scribe is not a sleepy “wait-and-see” biotech story. It enters public markets with something most early gene-editing companies can only dream about: strategic backing and collaboration history with large pharma, including Eli Lilly and Sanofi (SNY), which gives the story more commercial gravity than a science-fair poster board. That matters because in biotech, validation from a major partner often functions like a seal of approval, or at least a very expensive thumbs-up.

The story behind the surge

The market’s reaction reflects more than just IPO appetite; it reflects demand for differentiated platforms in a sector where investors increasingly want both innovation and a plausible path to value creation. Scribe’s pitch is centered on engineered CRISPR technologies and the promise of durable genetic medicines, which has enough long-term appeal to keep both scientists and speculators awake. The company also comes to market after a period of constructive momentum around its collaborations, including milestone progress tied to Lilly-linked programs.

What makes it investable

For investors, the appeal is straightforward: an early public biotech with marquee backing, a platform story, and a category that still commands attention when execution looks credible. The risk is equally straightforward: this is still an early-stage company, and the path from promising science to durable cash flow is long, expensive, and often littered with clinical potholes. In other words, it has the glamour of frontier biotech with the financial personality of a startup that has not yet met gravity.

Market takeaway

Scribe’s IPO is a reminder that biotech investors still love a story with three ingredients: deep-pocketed sponsors, a platform with scientific ambition, and a market willing to reward scarcity. If the listing holds up, it may signal that selective risk appetite is returning to gene editing, especially when a name arrives with LLY in the background and SCTX on the tape.

The Sources

[1] Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO https://www.bloomberg.com/news/articles/2026-07-24/eli-lilly-backed-scribe-therapeutics-jumps-67-after-upsized-ipo
[2] Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-pricing-upsized-010800484.html
[3] Eli Lilly and Company (LLY) https://finance.yahoo.com/quote/LLY/
[4] Scribe secures $129M in a rare gene editing IPO https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html
[5] Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech https://www.biospace.com/business/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-portfolios
[6] Scribe Enters Collaboration with Lilly’s Prevail to … https://globalgenes.org/raredaily/scribe-enters-collaboration-with-lillys-prevail-to-accelerate-in-vivo-crispr-based-therapies-for-neurological-and-neuromuscular-diseases/
[7] Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing https://endpoints.news/gene-editor-scribe-starts-second-half-ipo-spree-with-129m-listing/
[8] Scribe Therapeutics Achieves Second Success Milestone … https://www.scribetx.com/news/scribe-therapeutics-achieves-second-success-milestone-for-in-vivo-program-in-collaboration-with-eli-lilly-and-company
[9] Scribe Therapeutics https://www.scribetx.com/
[10] Scribe Therapeutics IPO Timeline and Financing Details https://forgeglobal.com/scribe-therapeutics_ipo/
[11] Sell or Invest in Scribe Stock Pre-IPO http://www.nasdaqprivatemarket.com/company/scribe/
[12] How to Optimize Content for Perplexity AI: A 2026 Tactical … https://contently.com/2026/02/20/how-to-optimize-content-for-perplexity-ai/
[13] CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/
[14] Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO https://www.marketscreener.com/news/eli-lilly-may-raise-stake-in-scribe-therapeutics-to-10-9-stake-through-ipo-ce7f51dbdb8bf723
[15] Scribe Announces Collaboration with Prevail, a Wholly … https://www.scribetx.com/news/scribe-announces-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-accelerate-in-vivo-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases
[16] Eli Lilly Stock Price Today | NYSE: LLY Live https://www.investing.com/equities/eli-lilly-and-co
[17] Scribe Therapeutics Raises $100M Series B Financing to … https://www.businesswire.com/news/home/20210331005648/en/Scribe-Therapeutics-Raises-$100M-Series-B-Financing-to-Further-Develop-CRISPR-by-Design-Platform-and-Pipeline-of-Breakthrough-Genetic-Medicines
[18] Eli Lilly: LLY Stock Price Quote & News https://robinhood.com/us/en/stocks/LLY/
[19] Scribe Therapeutics has put its IPO plans down on paper, … https://x.com/FierceBiotech/status/2079223507913699689
[20] How to Get Cited in Perplexity AI Search Results 2026 https://www.primal.co.th/ai/perplexity/
[21] Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech https://www.biospace.com/business/early-stage-scribe-wants-to-write-ipo-story-even-as-investors-favor-derisked-portfolios
[22] Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-pricing-upsized-010800484.html
[23] Eli Lilly May Raise Stake in Scribe Therapeutics to 10.9% Stake Through IPO https://www.marketscreener.com/news/eli-lilly-may-raise-stake-in-scribe-therapeutics-to-10-9-stake-through-ipo-ce7f51dbdb8bf723